Ivonecimab+化学療法は,高度な肺がん vs. ティスリーズマーブ+化学療法の生存率を改善し,副効果は減少した. Ivonescimab plus chemo improved survival in advanced lung cancer vs. tislelizumab plus chemo, with fewer side effects.

Ivonescimab+化学療法は 高度な非小性肺肺がんの生存率を著しく改善しました A Phase III trial, HARMONi-6, found that ivonescimab plus chemotherapy significantly improved progression-free survival in advanced squamous non-small cell lung cancer compared to tislelizumab plus chemotherapy, with a median PFS of 11.14 months versus 6.90 months, a 40% reduction in risk of progression or death. 利点はサブグループ間で一貫しており、この薬剤は良好な安全性プロファイルを示しました。 The benefit was consistent across subgroups, and the drug showed a favorable safety profile. 結果はESMO2025に提出され,The Lancetに掲載された. Results were presented at ESMO 2025 and published in The Lancet.